[1]潘 浩.依帕司他片辅助治疗对糖尿病视网膜病变患者SOD、TAOC及TNF-α水平的影响[J].医学信息,2020,33(05):100-101.[doi:10.3969/j.issn.1006-1959.2020.05.030]
　PAN Hao.Effects of Adjuvant Epalrestat on SOD,TAOC and TNF-α Levels in Patients with Diabetic Retinopathy[J].Medical Information,2020,33(05):100-101.[doi:10.3969/j.issn.1006-1959.2020.05.030]
点击复制

依帕司他片辅助治疗对糖尿病视网膜病变患者SOD、TAOC及TNF-α水平的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年05期
页码:
100-101
栏目:
临床研究
出版日期:
2020-03-01

文章信息/Info

Title:
Effects of Adjuvant Epalrestat on SOD,TAOC and TNF-α Levels in Patients with Diabetic Retinopathy
文章编号:
1006-1959（2020）05-0100-02
作者:
潘 浩
（天津市西青医院内分泌科，天津 300380）
Author(s):
PAN Hao
(Department of Endocrinology,Tianjin Xiqing Hospital,Tianjin 300380,China)
关键词:
糖尿病视网膜病变; 依帕司他片; SOD; TAOC; TNF-α
Keywords:
Diabetic retinopathy; Epalrestat tablets; SOD; TAOC; TNF-α
分类号:
R587.2；R774.1
DOI:
10.3969/j.issn.1006-1959.2020.05.030
文献标志码:
A
摘要:
目的 探究依帕司他片辅助治疗对糖尿病视网膜病变患者超氧化物歧化酶（SOD）、总抗氧化能力（TAOC）及肿瘤坏死因子-α（TNF-α）水平的影响。方法 选取2018年1月~2019年5月就诊于我院的糖尿病视网膜病变患者100例，按随机数字表法分为对照组和研究组，各50例。对照组采用前列地尔治疗，研究组在对照组基础上给予依帕司他片治疗。比较两组治疗效果、治疗前后SOD、TAOC及TNF-α水平。结果 研究组治疗总有效率（96.00%）高于对照组（84.00%）（P＜0.05）；治疗后，研究组SOD、TAOC水平高于对照组，TNF-α水平低于对照组（P＜0.05）。结论 依帕司他片辅助治疗糖尿病视网膜病变的疗效优于单用前列地尔，且有助于改善患者SOD、TAOC及TNF-α水平。
Abstract:
Objective To explore the effects of adjuvant epalrestat on superoxide dismutase (SOD), total antioxidant capacity (TAOC) and tumor necrosis factor-α (TNF-α) levels in patients with diabetic retinopathy. Methods A total of 100 patients with diabetic retinopathy who were admitted to our hospital from January 2018 to May 2019 were selected and according to the random number table method, divided into a control group and a study group, with 50 cases in each group. The control group was treated with alprostadil, and the research group was given epalrestat tablets on the basis of the control group. The treatment effects, SOD, TAOC and TNF-α levels were compared between the two groups. Results The total effective rate of treatment in the study group (96.00%) was higher than that in the control group (84.00%)(P<0.05). After treatment, the levels of SOD and TAOC in the study group were higher than those in the control group, and the levels of TNF-α were lower than those in the control group(P<0.05). Conclusion Epalrestat tablets are more effective in the treatment of diabetic retinopathy than alprostadil alone, and can help improve the levels of SOD, TAOC and TNF-α in patients.

参考文献/References:

[1]龙巧燕,陈玉华,刘姣,等.糖尿病视网膜病变的诊断与治疗研究进展[J].西部医学,2016,28(10):1478-1480.[2]董杰成,李转欢,李霞,等.前列地尔联合舒洛地特对糖尿病肾病及视网膜病变的防治作用[J].中国中西医结合肾病杂志,2018,19(7):610-612.[3]中华医学会眼科学会眼底病学组.我国糖尿病视网膜病变临床诊疗指南(2014年)[J].中华眼科杂志,2014,50(11):851-865.[4]桂玉敏,赵鸣,丁洁.糖尿病视网膜病变发病的内质网应激机制及羟苯磺酸钙的治疗作用研究[J].海南医学院学报,2016,22(11):1073-1074.[5]鹿丽,李冬娟,李明明,等.维生素B12联合依帕司他对糖尿病周围神经病患者血清SOD及MDA水平的影响[J].现代生物医学进展,2017,17(6):1146-1148,1159.

相似文献/References:

[1]郭 明,郑继伟,马丽平.25(OH)D3与糖尿病视网膜病变的关系研究[J].医学信息,2018,31(08):99.[doi:10.3969/j.issn.1006-1959.2018.08.031]
　GUO Ming,ZHENG Ji-wei,MA Li-ping.Study on the Relationship between 25(OH)D3 and Diabetic Retinopathy[J].Medical Information,2018,31(05):99.[doi:10.3969/j.issn.1006-1959.2018.08.031]
[2]闫宇梅.血清胱抑素C及同型半胱氨酸与2型糖尿病 视网膜病变的相关性分析[J].医学信息,2018,31(17):89.[doi:10.3969/j.issn.1006-1959.2018.17.027]
　YAN Yu-mei.Correlation between Serum Cystatin C and Homocysteine and Type 2 Diabetic Retinopathy[J].Medical Information,2018,31(05):89.[doi:10.3969/j.issn.1006-1959.2018.17.027]
[3]罗妮娜,金昌德,陈文莉.中西医结合护理在老年糖尿病视网膜病变低视力患者中应用及效果观察[J].医学信息,2018,31(19):165.[doi:10.3969/j.issn.1006-1959.2018.19.052]
　LUO Ni-na,JIN Chang-de,CHEN Wen-li.Application and Effect of Integrated Traditional Chinese and Western Medicine Nursing in Elderly Patients with Diabetic Retinopathy with Low Visual[J].Medical Information,2018,31(05):165.[doi:10.3969/j.issn.1006-1959.2018.19.052]
[4]宋晨音.他汀类药物在糖尿病治疗中的研究[J].医学信息,2022,35(17):166.[doi:10.3969/j.issn.1006-1959.2022.17.045]
　SONG Chen-yin.Study of Statins in the Treatment of Diabetes Mellitus[J].Medical Information,2022,35(05):166.[doi:10.3969/j.issn.1006-1959.2022.17.045]
[5]苟青青,李 鸿.糖尿病相关眼部改变及并发症的研究[J].医学信息,2022,35(18):153.[doi:10.3969/j.issn.1006-1959.2022.18.043]
　GOU Qing-qing,LI Hong.Study on Diabetes-related Ocular Changes and Complications[J].Medical Information,2022,35(05):153.[doi:10.3969/j.issn.1006-1959.2022.18.043]
[6]马 斌,王彩星,王金虹.基于文献计量学的我国2型糖尿病护理研究现状及热点分析[J].医学信息,2021,34(22):12.[doi:10.3969/j.issn.1006-1959.2021.22.004]
　MA Bin,WANG Cai-xing,WANG Jin-hong.Analysis of Current Status and Hot Spots in Nursing Research of Type 2 Diabetes Mellitus in China Based on Bibliometrics[J].Medical Information,2021,34(05):12.[doi:10.3969/j.issn.1006-1959.2021.22.004]
[7]孙天慧,谭晓霞,连晓芬,等.2型糖尿病合并视网膜病变的影响因素分析[J].医学信息,2020,33(21):94.[doi:10.3969/j.issn.1006-1959.2020.21.027]
　SUN Tian-hui,TAN Xiao-xia,LIAN Xiao-fen,et al.Analysis of Influencing Factors of Type 2 Diabetes with Retinopathy[J].Medical Information,2020,33(05):94.[doi:10.3969/j.issn.1006-1959.2020.21.027]
[8]李 娟,冯双双,康京京,等.尿β2微球蛋白水平与2型糖尿病患者视网膜病变和肾脏病变的相关性[J].医学信息,2020,33(19):99.[doi:10.3969/j.issn.1006-1959.2020.19.029]
　LI Juan,FENG Shuang-shuang,KANG Jing-jing,et al.Correlation Between Urine β2 Microglobulin Level and Retinopathy and Nephropathy in Type 2 Diabetic Patients[J].Medical Information,2020,33(05):99.[doi:10.3969/j.issn.1006-1959.2020.19.029]
[9]彭 越,高 宇,王云飞,等.VEGF在糖尿病视网膜病变发病机制中的作用[J].医学信息,2021,34(05):36.[doi:10.3969/j.issn.1006-1959.2021.05.011]
　PENG Yue,GAO Yu,WANG Yun-fei,et al.The Role of VEGF in the Pathogenesis of Diabetic Retinopathy[J].Medical Information,2021,34(05):36.[doi:10.3969/j.issn.1006-1959.2021.05.011]
[10]杨文彦.雷珠单抗玻璃体腔注射联合激光治疗对糖尿病视网膜病变患者视力水平的影响[J].医学信息,2023,36(11):110.[doi:10.3969/j.issn.1006-1959.2023.11.021]
　YANG Wen-yan.Effect of Intravitreal Injection of Ranibizumab Combined with Laser Therapy on Visual Acuity in Patients with Diabetic Retinopathy[J].Medical Information,2023,36(05):110.[doi:10.3969/j.issn.1006-1959.2023.11.021]

更新日期/Last Update: 2020-03-01